Non-immunosuppressive treatment of IgA nephropathy

IgA nephropathy is the most common glomerular nephropathy, with progression to renal failure in 20-40% of patients. Non-immunosuppressive therapies have become central to its management, improving blood pressure and reducing proteinuria, while limiting the risks of long-term immunosuppressive therapy. This Cochrane review is an update of the one already carried out in 2011 to assess the benefits and drawbacks of non-immunosuppressive treatments in adults and children. 24 new studies, including 2,018 participants, have been added to the studies already considered, bringing the total number of studies to 80 for 4,856 participants. Generally speaking, the clinical trials available are few in number, involve small samples and are of insufficient duration to assess the potential long-term benefits of non-immunosuppressive treatments in IgA nephropathy.